Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

EJNMMI Research

Table 1 Characteristics of the study population

Patient no	Age	Indication	Previous treatment or other notes	PSA (µg/L)	Gleason	Tracer	Dose (MBq)
1	70	Primary staging		6.4	7	[⁶⁸Ga]Ga-PSMA-11	151
2	53	Primary staging		7.2	7	[⁶⁸Ga]Ga-PSMA-11	151
3	68	Primary staging		30	7	[⁶⁸Ga]Ga-PSMA-11	163
4	67	Relapse	Prostatectomy and LN extraction	4	8	[⁶⁸Ga]Ga-PSMA-11	198
5	78	Primary staging		11	7	[⁶⁸Ga]Ga-PSMA-11	182
6	63	Primary staging	Increased prostate size, negative previous biopsies	35	NA	[⁶⁸Ga]Ga-PSMA-11	135
7	60	Primary staging		47	8	[⁶⁸Ga]Ga-PSMA-11	177
8	71	Primary staging		95	9	[⁶⁸Ga]Ga-PSMA-11	175
9	57	Primary staging		160	7	[⁶⁸Ga]Ga-PSMA-11	204
10	69	Primary staging		14.6	7	[⁶⁸Ga]Ga-PSMA-11	194
11	75	Progression	Medical castration	707.7	7	[¹⁸F]PSMA-1007	151
12	73	Relapse	Prostatectomy	0.2	8	[¹⁸F]PSMA-1007	201
13	66	Progression	Active surveillance	9.6	6	[¹⁸F]PSMA-1007	181
14	63	Primary staging		32.5	8	[¹⁸F]PSMA-1007	209
15	64	Relapse	Prostatectomy + RT	0.2	7	[¹⁸F]PSMA-1007	197
16	71	Primary staging	Increased prostate size, negative previous biopsies	14	NA	[¹⁸F]PSMA-1007	240
17	65	Primary staging		72.4	8	[¹⁸F]PSMA-1007	236
18	78	Primary staging		31.6	7	[¹⁸F]PSMA-1007	205
19	68	Primary staging		5.1	9	[¹⁸F]PSMA-1007	205
20	71	Primary staging		5.9	7	[¹⁸F]PSMA-1007	164